

---

**Table of Contents**

---

<b>1. Kit Contents</b>	<b>2</b>
<b>2. Materials Required but Not Supplied</b>	<b>2</b>
<b>3. Introduction</b>	<b>3</b>
3.1 Principles of FRET and TR-FRET	3
3.2 Assay Overview	3
<b>4. Instrument Settings</b>	<b>4</b>
4.1 Important Considerations	4
4.2 Settings for Filter-Based Instruments:	5
4.3 Settings for Monochromator-Based Instruments:	5
4.4 Settings for CCD-based instruments	6
<b>5. Guidelines and Recommendations</b>	<b>6</b>
5.1 Reagent Handling	6
5.2 Ligand Dilutions	6
5.3 Solvent Tolerance	7
5.4 Note on Reagent Order of Addition	7
5.5 Incubation Conditions	7
<b>6. Agonist Assay</b>	<b>8</b>
6.1 Agonist Assay—Procedure	8
6.2 Plate Layout	10
6.3 Agonist Assay—Data Analysis	10
6.4 Agonist Assay—Reagent Volumes and Controls	11
6.5 Agonist Assay—Representative Data	12
<b>7. Antagonist Assay</b>	<b>12</b>
7.1 Calculating the EC <sub>50</sub> from the Agonist Assay	13
7.2 Antagonist Assay	13
7.3 Plate Layout	14
7.4 Antagonist Assay—Data Analysis	14
7.5 Antagonist Assay—Reagent Volumes and Controls	15
<b>8. Assay Pharmacology</b>	<b>16</b>
<b>9. References</b>	<b>18</b>
<b>10. Notice to Purchaser</b>	<b>18</b>

## 1. Kit Contents

The LanthaScreen® TR-FRET Vitamin D Receptor Coactivator Assay, catalog no. PV4554, contains the following:

Component	Composition	Amount	Storage Temp.	Individual Catalog no.
Fluorescein-TRAP220/DRIP-2 peptide (Rachez, <i>et al.</i> , 2000)	100 µM in 50 mM HEPES, pH 7.5 Sequence: NTKNHPMLMNLKDNPAQD	100 µL	-20°C	PV4549
VDR LBD, GST	VDR ligand-binding domain in a buffer (pH 7.5) containing protein stabilizing reagents and 20% glycerol. See the Certificate of Analysis for the recommended molar concentration for this kit.	5 µg	-80°C	PV4551
LanthaScreen® Tb-anti-GST antibody	Terbium labeled anti-GST antibody in HEPES buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM HEPES pH 7.5). See the Certificate of Analysis for lot-specific concentration	25 µg	-20°C	PV3550
TR-FRET Coregulator Buffer G	Proprietary buffer (pH 7.5) (without glycerol)	2 × 25 mL	4°C	PV4553
DTT, 1 M	In water	1 mL	-20°C or -80°C	P2325
LanthaScreen® Tb Instrument Control Kit	Reagents sufficient to test instrument performance to generate TR-FRET signal	1 kit	Various—see kit protocol	PV5591

## 2. Materials Required but Not Supplied

The following materials are required but not supplied in the kit:

- A fluorescence plate reader with excitation capabilities at 340 nm and with the appropriate filter sets installed for detecting the fluorescent emission signals of terbium at 495 nm and fluorescein at 520 nm (see Section 4).
- Pipetting devices for 1–1000 µL volumes, suitable repeater pipettors, or multi-channel pipettors.
- Black, 384-well assay plates. We recommend black Corning® 384-well, low-volume, round-bottom (non-binding surface) assay plates; Corning #3676. Other plate types may give satisfactory results as well but have not been fully tested.
- 96-well polypropylene plates that can accommodate a 300-µL volume per well for the ligand serial dilutions in 100% DMSO. Polypropylene plates are required since they are tolerant of DMSO. We recommend Nalgene® Nunc™ #249944.
- A known VDR agonist, such as calcitriol, to serve as a positive control. We recommend Sigma D1530.
- DMSO to perform serial dilutions. We recommend Fluka 41647.

**For Technical Support for this or other Invitrogen Discovery Sciences Products, dial 760 603 7200, select option 3, extension 40266**  
For information on frequently asked questions regarding the LanthaScreen™ technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## 3. Introduction

Invitrogen's LanthaScreen® TR-FRET Vitamin D Receptor Coactivator Assay provides a sensitive and robust method for high-throughput screening of potential VDR ligands as agonists of coactivator recruitment. The kit uses a terbium-labeled anti-GST antibody, a fluorescein-labeled coactivator peptide, and a VDR ligand-binding domain that is tagged with glutathione-S-transferase (GST) in a homogenous mix-and-read assay format. This kit contains enough reagents for 800 assays of 20  $\mu$ L each.

### 3.1 Principles of FRET and TR-FRET

For screening libraries of compounds, time-resolved FRET (TR-FRET) is a recognized method for overcoming interference from compound autofluorescence or light scatter from precipitated compounds. The premise of a TR-FRET assay is the same as that of a standard FRET assay: when a suitable pair of fluorophores is brought within close proximity of one another, excitation of the first fluorophore (the donor) can result in energy transfer to the second fluorophore (the acceptor). This energy transfer is detected by an increase in the fluorescence emission of the acceptor and a decrease in the fluorescence emission of the donor. In HTS assays, FRET is often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells and corrects for quenching effects due to colored compounds.

In contrast to standard FRET assays, TR-FRET assays use a long-lifetime lanthanide chelate as the donor species. Lanthanide chelates are unique in that their excited-state lifetime (the average time that the molecule spends in the excited state after accepting a photon) can be on the order of a millisecond or longer. This is in sharp contrast to the lifetime of common fluorophores used in standard FRET assays, which are typically in the nanosecond range. Because interference from autofluorescent compounds or scattered light from precipitated compounds is also on the nanosecond timescale, these factors can negatively impact standard FRET assays. To overcome these interferences, TR-FRET assays are performed by measuring FRET after a suitable delay, typically 100 microseconds after excitation by a flashlamp excitation source in a microtiter plate reader. This delay not only overcomes interference from background fluorescence or light scatter, but also avoids interference from direct excitation due to the non-instantaneous nature of the flashlamp excitation source.

The most common lanthanides used in TR-FRET assays for HTS are terbium (Tb) and europium (Eu). Terbium offers unique advantages over europium when used as the donor species in a TR-FRET assay. In contrast to europium-based systems that employ the relatively large protein APC as the acceptor, terbium-based TR-FRET assays can use common small molecule fluorophores such as fluorescein as the acceptor. It is straightforward (and inexpensive) to directly label a molecule such as a peptide with fluorescein for use in terbium-based TR-FRET assays. In addition, the assay format is simpler than using a biotinylated peptide that would then be indirectly labeled via streptavidin-mediated recruitment of APC. Therefore, the use of directly labeled molecules (in this case the Fluorescein-coactivator peptide) in a terbium-based TR-FRET assay simplifies assay development by reducing the number of components to optimize, avoids problems due to steric interactions involving large APC conjugates, reduces costs, and improves kinetics.

### 3.2 Assay Overview


Binding of agonist to the nuclear receptor (Figure 1) causes a conformational change around helix 12 in the ligand binding domain, resulting in higher affinity for the coactivator peptide. When the terbium label on the anti-GST antibody is excited at 340 nm, energy is transferred to the fluorescein label on the coactivator peptide and detected as emission at 520 nm.

When running the LanthaScreen® TR-FRET Vitamin D Receptor Coactivator Assay, VDR-LBD is added to ligand test compounds followed by addition of a mixture of the fluorescein-coactivator peptide and terbium anti-GST antibody. After an incubation period at room temperature, the TR-FRET ratio of 520:495 emissions is calculated and can be used to determine the  $EC_{50}$  from a dose response curve of the compound. Based on the biology of the VDR-coactivator peptide interaction, this ligand  $EC_{50}$  is a composite value representing the amount of ligand required to bind to receptor, effect a conformational change, and recruit coactivator peptide (see Figure 1).

The recommended concentration of VDR-LBD GST, and fluorescein-coactivator peptide have been optimized to produce a satisfactory assay window ( $Z' > 0.5$ ) while using the lowest receptor concentration to achieve the best sensitivity to tight binding ligands. Using VDR with other coactivator peptides may require different optimal concentrations. For a list of available peptides, visit the following web page:

<http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Drug-Discovery/Target-and-Lead-Identification-and-Validation/Nuclear-Receptor-Biology/NRB-misc/Biochemical-Assays/Available-Fluorescent-Coregulator-Peptides.html>

For additional information, contact Technical Support.



**Figure 1. Principle of the nuclear receptor (NR) agonist dependent coactivator peptide recruitment assay:** Tb-anti-GST antibody indirectly labels the nuclear receptor by binding to the GST tag. Binding of the agonist to the NR causes a conformational change which results in an increase in the affinity of the NR for a coactivator peptide. The close proximity of the fluorescently labeled coactivator peptide to the terbium-labeled antibody causes an increase in the TR-FRET signal.

## 4. Instrument Settings

The LanthaScreen® Tb Instrument Control Kit (catalog no. PV5591) has been included to facilitate instrument set-up. We recommend that you use this kit to verify your instrument settings before proceeding with any Nuclear Receptor Biology. For additional help in setting up your instrument to perform LanthaScreen® TR-FRET assays, contact Invitrogen Discovery Sciences technical support at 800-955-6288 (select option 3 and enter 40266) or email [drugdiscoverytech@invitrogen.com](mailto:drugdiscoverytech@invitrogen.com). Visit <http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Drug-Discovery/DD-Misc/instrument-compatibility-portal.html> for instrument specific information, including step-by-step instrument-specific guides for optimizing LanthaScreen® TR-FRET assays on your particular instrument.

LanthaScreen® Technology has been tested on a variety of microplate readers. These include filter-based instruments (Tecan Ultra, GENiosPro™, and Infinite F500; BMG LABTECH PHERAstar; BioTek Synergy2 and Synergy4; PerkinElmer EnVision™ and Victor™; and Molecular Devices Analyst™), CCD-based imagers (PerkinElmer ViewLux™), and monochromator-based instruments (Tecan Safire<sup>2</sup> and Infinite M1000™).


### 4.1 Important Considerations

The excitation and emission spectra of terbium and fluorescein are shown in Figure 2. To read a LanthaScreen® TR-FRET assay, the instrument is configured to excite the terbium donor around 340 nm and read the terbium emission peak that is centered at approximately 490 nm and the fluorescein emission that is centered at approximately 520 nm.

Filter bandwidths must be able to separate the terbium emission signal from the fluorescein emission signal. For this reason, a standard fluorescein filter cannot typically be used. After taking the measurements, the signal from the fluorescein emission is divided (or “ratioed”) by the terbium signal to provide a TR-FRET emission ratio and improve the  $Z'$  for the assay.

**For Technical Support for this or other Invitrogen Discovery Sciences Products, dial 760 603 7200, select option 3, extension 40266**  
For information on frequently asked questions regarding the LanthaScreen™ technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

## Spectra of Terbium and Fluorescein



**Figure 2.** Excitation and emission spectra of fluorescein and terbium.

Aside from filter choices, other instrument settings are similar to the settings used with europium-based technologies. A delay time of 100  $\mu$ s followed by a 200- $\mu$ s integration time is typical for a LanthaScreen® TR-FRET assay. The number of flashes or measurements per well is highly instrument dependent and should be set as advised by your instrument manufacturer.

### 4.2 Settings for Filter-Based Instruments:

Excitation	340 nm filter (30 nm bandwidth)
Fluorescein Emission	520 nm filter (25 nm bandwidth)
Terbium Emission	490 or 495 nm filter (10 nm bandwidth)
Dichroic Mirror	Fluorescein (Tecan Ultra, GENios, Infinite™, GENiosPro™, Infinite™) LANCE/TRF (EnVision, VictorEnVison™, Victor™) 380 nm (preferred) or 400 nm (Analyst™) Built In (PHERAstar™)
Delay Time	100 $\mu$ s
Integration Time	200 $\mu$ s

Note that excitation filters with similar bandwidths will give satisfactory performance as long as the center wavelength falls at or between 330 nm and 340 nm. Excitation and emission filters (from Chroma Technologies) for most microplate readers are available directly from Invitrogen at [www.invitrogen.com/LanthaScreen](http://www.invitrogen.com/LanthaScreen). A LanthaScreen® TR-FRET filter optical module is available directly from BMG LABTECH for use on the PHERAstar. Perkin Elmer Envision™ users may require a specific filter holder that is available from PerkinElmer as part # 2100-8110 for a package of 10.

### 4.3 Settings for Monochromator-Based Instruments:

Excitation	332 nm (20 nm bandwidth)
Fluorescein Emission	515 nm (20 nm bandwidth)
Terbium Emission	486 nm (20 nm bandwidth)
Delay Time	100 $\mu$ s
Integration Time	200 $\mu$ s

**For Technical Support for this or other Invitrogen Discovery Sciences Products, dial 760 603 7200, select option 3, extension 40266**  
For information on frequently asked questions regarding the LanthaScreen™ technology, please go to [www.invitrogen.com/lanthascreen](http://www.invitrogen.com/lanthascreen)

Some monochromator-based instruments, such as the Tecan Infinity M1000™, allow each emission wavelength to be individually set. In this case, match the settings to those listed for the filter-based instruments. When the bandwidths of the two emission wavelengths cannot be individually set, use the general settings for monochromator-based instruments listed in the table above as a guide.

Note that not all monochromator-based instruments are capable of a 20-nm bandwidth. Smaller bandwidth settings may be used, but with a decrease in assay performance. Additionally, we have found that while some monochromator based instruments (Tecan Safire<sup>2</sup>™, Tecan Infinity M1000™) give satisfactory performance in LanthaScreen® TR-FRET assays, other monochromator-based instruments (e.g., Tecan Safire™ and Molecular Devices Gemini™ series, Molecular Devices SpectraMax M2 and M5) may not be optimal for detection, although some change in signal and a ratio may still be observed. We have also found that with some assays, white plates give better assay performance when using monochromator-based instruments. In filter-based instruments the difference is typically negligible.

#### 4.4 Settings for CCD-based instruments

Visit <http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Drug-Discovery/DD-Misc/instrument-compatibility-portal.html> and following link to the ViewLux™ for a step-by-step guide to optimizing LanthaScreen® TR-FRET assays on the PerkinElmer ViewLux™.

## 5. Guidelines and Recommendations

---

### 5.1 Reagent Handling

#### ***VDR-LBD, GST***

Store the GST-tagged VDR-LBD at –80°C. Thaw on ice before use and perform all dilutions while on ice. Mix by gentle pipetting or inversion of the tube. Never vortex the VDR-LBD stock or dilutions. We recommend aliquoting the VDR-LBD after the first thaw for subsequent experiments.

#### ***TR-FRET Coregulator Buffer G***

Thaw TR-FRET Coregulator Buffer G at room temperature upon receipt. Mix well before first use, as the buffer may not have thawed evenly. The buffer should be stored at 4°C. Mix well before each use.

#### ***LanthaScreen® TR-FRET anti-GST Antibody***

Store Tb anti-GST antibody at –20°C and thaw before use. To help minimize the potential effect of aggregated antibody observed as spikes in the 495 channel, which in turn affect the 520/495 ratio, centrifuge the stock vial of Tb anti-GST Antibody (~10,000 rpm for 10 minutes) prior to use. After centrifugation, pipet the quantity of antibody needed for your aliquots from the top of the liquid, thereby minimizing the potential mixing of any precipitate that has been spun to the bottom of the tube.

#### ***Fluorescein-TRAP220/DRIP-2 Coactivator Peptide***

Store fluorescein-TRAP220/DRIP-2 coactivator peptide at –20°C. Thaw and mix before use.

### 5.2 Ligand Dilutions

The procedure described below involves diluting the ligand to 100X in DMSO followed by transfer into complete assay buffer, resulting in a 2X ligand, 2% DMSO dilution. This may be done in a DMSO-tolerant assay plate or tubes such as those made from polypropylene or HDPE. Dilution in DMSO reduces the occurrence of compound precipitation while performing the dilution series, reduces sticking to plastics, improves IC<sub>50</sub> reproducibility and maintains constant DMSO in all wells. After addition of all reagents to the assay, the final concentration will be 1X ligand and 1% DMSO. We suggest using this method for compound dilutions.

**Note:** Handling of some ligands can be problematic due to their tendency to stick to various plastics. These ligands may show varying degrees of stickiness, causing differences in the actual concentration of the ligand, depending on the type of pipette tips and plates used in the set up of the assay. Therefore, you may observe different EC<sub>50</sub> values than reported here.

### 5.3 Solvent Tolerance

The assay was validated in the presence of 1% DMSO. However, the assay has been performed with up to 8% DMSO, 2% ethanol, and 2% methanol (in addition to the 1% DMSO present from the ligand dilution) with good results. The use of higher concentrations of ethanol or methanol may still yield a robust assay, however a decreased assay window was observed with 4% and 8% of these solvents.

### 5.4 Note on Reagent Order of Addition

The assay was validated using three additions per well in which VDR-LBD was added to agonist dilutions, followed by the addition of pre-mixed fluorescein-TRAP220/DRIP-2 coactivator peptide and Tb anti-GST antibody (agonist, receptor, peptide/antibody). A pre-mixture of VDR-LBD, fluorescein-TRAP220/DRIP-2 coactivator peptide, and Tb anti-GST antibody may also be added to the agonist dilutions for a total of 2 additions per well, although the assay was not fully validated in this manner and equilibration times may differ in this format. The impact of premixing on EC<sub>50</sub> and IC<sub>50</sub> values has not been evaluated. It is important to consider the effect of time and temperature on this three-component pre-mixture when developing the assay.

### 5.5 Incubation Conditions

#### *Incubation Time*

The incubation time can be set by the user. As a guide, results for various time points using calcitriol as the agonist are shown in Table 1 below. The EC<sub>50</sub> and Z' are stable from 1 to 24 hours (Table 1). We suggest maintaining the same incubation time and temperature during testing and screening for consistent results.

Incubation Time (hours)	EC <sub>50</sub> calcitriol	Z'-Factor
1	0.58 nM	0.63
2	0.54 nM	0.79
4	0.53 nM	0.77
6	0.56 nM	0.82
24	0.81 nM	0.76

**Table 1. Effect of Incubation Time on Assay Performance.** Sample data represents mean values from 3 separate experiments (n = 24). EC<sub>50</sub> values were determined by fitting the data to a sigmoidal dose response (variable slope) equation in GraphPad™ Prism® 4.0 (data not shown). Z'-factors were calculated using the method of Zhang *et al.* (Zhang *et al.*, 1999) on the 24 replicates of maximum agonist and no agonist (agonist mode). Z'-factor is an indication of the robustness of the assay, where values ≥ 0.5 indicate an excellent assay, while a value of 1 indicates a theoretically ideal assay with no variability.

#### *Temperature*

We recommend that assays be conducted at room temperature (20–23°C).

## 6. Agonist Assay

The procedure in this section describes a method for determining the  $EC_{50}$  of an agonist ( $n = 4$ ) and the  $Z'$  factor for maximum agonist and no agonist controls ( $n = 24$ ) using the agonist-induced recruitment of fluorescein TRAP220/DRIP-2 coactivator peptide to VDR-LBD. The only variable is the agonist concentration. All other assay components (VDR-LBD, peptide, Tb anti-GST antibody) are fixed at concentrations optimized to produce a satisfactory assay window ( $Z'$ -factor  $>0.5$ ) while using the lowest receptor concentration to achieve the best sensitivity to tight binding ligands. Although a higher concentration of nuclear receptor may give a larger TR-FRET signal window, it will compromise the sensitivity of the assay with regard to differentiating tight binding ligands. The recommended final concentrations are listed in the following table. If a component concentration is changed, the concentrations of the other components may need to be reoptimized.

Component	Final Assay Concentration
Fluorescein-TRAP220/DRIP-2	100 nM
Tb anti-GST antibody	2 nM
VDR-LBD GST	See the Certificate of Analysis for the recommended molar concentration for this kit

### 6.1 Agonist Assay—Procedure

#### Prepare Complete Buffer G and Agonist Controls

**Note:** The VDR-LBD should be thawed on ice just prior to use. Equilibrate all other assay components to room temperature.

1. Prepare Complete Buffer G by adding 1 M DTT to the TR-FRET Coregulator Buffer G provided in the kit for a final concentration of 5 mM DTT. Complete Buffer G must be prepared fresh daily.

**For example:** Add 30  $\mu$ L of 1 M DTT to 5.97 mL of TR-FRET Coregulator Buffer G.

**Note:** Keep Complete Buffer G at room temperature for the preparation of all reagents except for 4X VDR-LBD, which should be prepared with cold buffer. Reserve an appropriate volume of buffer **on ice** for preparation of 4X VDR-LBD (see step 8 for concentrations and example volumes needed).

**Note:** TR-FRET Coregulator Buffer G is a specially formulated buffer that has been optimized to work with this kit. To ensure performance of this assay, we highly recommend using Buffer G as provided with the kit.

2. For the “no agonist” controls, add DMSO to Complete Buffer G for a final concentration of 2% DMSO (2X solvent). Add 10  $\mu$ L of this buffer containing DMSO to row C, columns 1–24 of a 384-well assay plate (see the plate layout in Section 6.2).

**For example:** Add 10  $\mu$ L of DMSO to 490  $\mu$ L of Complete Buffer G.

3. Prepare a solution of control agonist (we recommend calcitriol) at 100X of the final desired maximum starting concentration using 100% DMSO.

**For example:** If the final desired maximum starting concentration of agonist is 1  $\mu$ M, prepare a solution of 100  $\mu$ M agonist in 100% DMSO.

4. For the “maximum agonist” controls, dilute the 100X agonist solution from step 3 to 2X using Complete Buffer G. Add 10  $\mu$ L of this solution to row D, columns 1–24 in the 384-well assay plate (see the plate layout in Section 6.2).

**For example:** Add 10  $\mu$ L of 100X agonist solution to 490  $\mu$ L of Complete Buffer G.



### Prepare 2X Agonist Dilution Series

**Note:** Although steps 5 and 6 below require more pipetting than other methods of preparing a serial dilution of agonist, we have found that this approach provides a robust method for preparing the dilution series without problems due to agonist solubility. Dilution with 100% DMSO facilitates compound solubility during serial dilutions, which is important for obtaining consistent EC<sub>50</sub> values.

5. Prepare a 12-point 100X dilution series of agonist in a 96-well polypropylene plate (DMSO tolerant) by serially diluting the 100X agonist solution from step 3 using 100% DMSO. We recommend a 3-fold dilution series.

**For example:** Add 20 µL of 100% DMSO to wells A2–A12 in a 96-well polypropylene plate. To well A1, add 30 µL of the 100X agonist solution prepared in step 3. Perform a three-fold serial dilution by transferring 10 µL of the 100X agonist solution from well A1 to the 20 µL of DMSO in well A2. Mix by pipetting up and down. Repeat for wells A2–A12.

6. Dilute each 100X agonist serial dilution from step 5 to 2X using Complete Buffer G.

**For example:** Transfer 5 µL of each of the 100X agonist serial dilutions from row A of the 96-well plate (wells A1–A12) to row B (wells B1–B12). Add 245 µL of Complete Buffer G to each well in row B of the 96-well plate. Mix by pipetting up and down.

7. To assay four replicates of each ligand concentration, transfer 10 µL of each 2X ligand serial dilution to the 384-well assay plate according to the plate layout in Section 6.2.

**For example:** Using the 12-channel pipette transfer 10 µL aliquots from row B of the 96 well plate to alternate columns across row A of the 384-well plate, A1, A3, A5, A7, etc. Continue this process for row A, this time pipetting into A2, A4, A6, etc. Repeat this process for row B of the 384-well plate.

Alternatively, use a 16-channel pipette where two tips fit into one well of the 96-well plate, then transfer to individual wells of the 384-well assay plate in rows A and B. Repeat to complete all of the columns (1–24).

With either method, wells A1, A2, B1, and B2 all contain the highest concentration of ligand from B1 of the 96-well plate. Wells A3, A4, B3, B4 all contain the next concentration of ligand from B2 of the 96-well plate, and so forth, for four replicates of each concentration with constant percent DMSO.

### Prepare 4X VDR-LBD

8. Prepare 4X VDR-LBD using **cold** Complete Buffer G from step 1. The recommended molar concentration of VDR for this kit is listed on the Certificate of Analysis. **Never vortex the VDR-LBD stock or dilutions.** Mix by pipetting or gentle inversion. Keep this solution on ice until needed for use in the assay.

**For example:** If the VDR-LBD has a stock concentration of 4000 nM and the recommended concentration for this kit is 1.0 nM, prepare a 4X solution at 4 nM by adding 2 µL of VDR-LBD stock to 1998 µL of **cold** Complete Buffer G.

9. Add 5 µL of 4X VDR-LBD to rows A–D, columns 1–24 of the 384-well assay plate. We recommend adding from low to high concentration of ligand (right to left) to prevent ligand carry over.

### Prepare 4X Fluorescein-TRAP220/DRIP-2/4X Tb anti-GST Antibody

10. Prepare a solution containing 400 nM fluorescein-TRAP220/DRIP-2 (4X) and 8 nM Tb anti-GST antibody (4X) using Complete Buffer G at room temperature. The stock concentration of fluorescein-TRAP220/DRIP-2 is 100 µM and the concentration of Tb anti-GST antibody is indicated on both the vial label and the Certificate of Analysis (0.5 mg/mL = ~3.4 µM antibody).


**For example:** Add 4 µL of 100 µM fluorescein-TRAP220/DRIP-2 and 2.4 µL of 3.4 µM Tb anti-GST antibody to 994 µL of Complete Buffer G.

- Add 5  $\mu$ L of 4X peptide/4X antibody solution to rows A–D, columns 1–24 of the 384-well assay plate (see plate layout in Section 6.2).

### Plate Incubation and Reads

- Briefly and gently mix the 384-well plate on a plate shaker and incubate at room temperature protected from light for the chosen equilibration time. The plate may be sealed with a cover to minimize evaporation.
- Note:** If you decide to use assay plates that are **not** coated, such as the Corning 3677 plates, drops may cling to the side of the wells during additions to the plate. It is critical that the plates be gently tapped or centrifuged to ensure that all reagents reach the bottom of the well.
- Read the plate at wavelengths of 520 nm and 495 nm using the instrument settings described in Section 4. If using a plate seal, spin the sealed plate in a centrifuge with an appropriate balance to spin down any condensation on the bottom of the seal, shake the plate gently, and read. Then proceed to data analysis as described in the next section.

## 6.2 Plate Layout



## 6.3 Agonist Assay—Data Analysis

Calculate the TR-FRET ratio by dividing the emission signal at 520 nm by the emission signal at 495 nm. Generate a binding curve by plotting the emission ratio vs. the log [ligand]. To determine the EC<sub>50</sub> value, fit the data using an equation for a sigmoidal dose response (varying slope), as provided by GraphPad™ Prism® 4.0 or another comparable graphing program.

The “maximum agonist” and “no agonist” control data can be used to calculate Z'-factor based on the equation of Zhang *et al.* (Zhang *et al.*, 1999).

**Note:** The ligand EC<sub>50</sub> determined in the assay is a composite of multiple equilibria, including ligand binding to receptor and peptide binding to ligand/receptor complex.

## 6.4 Agonist Assay—Reagent Volumes and Controls


The following table summarizes the reagent volumes, order of addition, and potential controls for developing an agonist mode assay. The protocol in Section 6.1 may be adapted to screen test compounds using the following summary table as a guide.

Assay	Reagent Additions	Purpose
Test Compound	<ol style="list-style-type: none"> <li>10 µL 2X Test Compound (or dilution series)</li> <li>5 µL 4X VDR-LBD</li> <li>5 µL 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab</li> </ol>	Assess coactivator recruitment upon binding of test compound.
Positive Control (Max agonist)	<ol style="list-style-type: none"> <li>10 µL 2X agonist (or dilution series)</li> <li>5 µL 4X VDR-LBD</li> <li>5 µL 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab</li> </ol>	Assess coactivator recruitment upon binding of a known VDR agonist.
Negative Control (No agonist)	<ol style="list-style-type: none"> <li>10 µL Assay Buffer with 2X Compound Solvent</li> <li>5 µL 4X VDR-LBD</li> <li>5 µL 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab</li> </ol>	Provides baseline signal for the assay, including possible ligand-independent coactivator recruitment.
No VDR-LBD Control	<ol style="list-style-type: none"> <li>10 µL Assay Buffer 2X Compound Solvent</li> <li>5 µL Complete Buffer G</li> <li>5 µL 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab</li> </ol>	Can be compared to the negative control to determine ligand-independent coactivator recruitment. May also be used to determine diffusion enhanced TR-FRET.*

**Note:** All controls should contain the same percentage of solvent as the wells containing test compound.

\* Diffusion enhanced TR-FRET occurs when the donor (Tb-anti-GST Antibody) passes by the acceptor (FI-TRAP220) in solution during the excited state lifetime of the donor and is not related to a binding event. At higher concentrations of donor or acceptor, the probability of this occurrence increases and results in a larger background signal due to diffusion enhanced TR-FRET.

## 6.5 Agonist Assay—Representative Data



Time Point	EC <sub>50</sub> (nM)
1 hour	0.82
2 hour	0.67
4 hour	0.67
6 hour	0.70
24 hour	1.00

**Figure 3. Representative experiment of LanthaScreen® TR-FRET VDR-Coactivator assay.** Assay composition: serial dilution of agonist calcitriol, 0.3 nM VDR-LBD, 100 nM Fluorescein TRAP220/DRIP-2, and 2 nM Tb anti-GST antibody. Results for 1-hour, 2-hour, 4-hour, 6-hour and 24-hour incubations are shown with the corresponding EC<sub>50</sub> values. The curves were generated using a sigmoidal dose response (variable slope) equation in GraphPad™ Prism® 4.0.

## 7. Antagonist Assay

Although we were not aware of a commercial antagonist for VDR at the time this assay was developed, the procedure described below describes a general method that could be performed to assess antagonist activity. For this approach, we define antagonist as a compound that does not necessarily recruit or displace coregulator peptides by itself, but does competitively displace an agonist that can then result in displacement of coregulator peptides relative to the agonist.

Component	Final Assay Concentration
Fluorescein-TRAP220/DRIP-2	100 nM
Tb anti-GST antibody	2 nM
Agonist concentration	EC <sub>80</sub> calculated from assay performed in agonist mode
VDR LBD-GST	See Certificate of Analysis for the recommended molar concentration for this kit

**Note:** We recommend determining the EC<sub>80</sub> of the agonist as described in section 6.0. Although a concentration of agonist greater than the EC<sub>80</sub> will give a larger assay window, the sensitivity of the assay as defined by the ability to identify antagonists will be compromised.

## 7.1 Calculating the EC<sub>80</sub> from the Agonist Assay

Calculate the EC<sub>80</sub> from the agonist assay, using the EC<sub>50</sub> and Hill Slope determined from the curve fit of the sigmoidal dose response (variable slope) equation:

$$EC_{80} = 10^{((\log EC_{50}) + ((1/\text{Hill Slope}) \times \log(80/(100 - 80))))}$$

## 7.2 Antagonist Assay

### Prepare Complete Buffer G and Controls

1. Prepare Complete Buffer G by adding 1 M DTT to the TR-FRET Coregulator Buffer G provided in the kit for a final concentration of 5 mM DTT. Complete Buffer G must be prepared fresh daily.

*For example:* Add 30 µL of 1 M DTT to 5.97 mL of TR-FRET Coregulator Buffer G.

2. For the “no antagonist” controls (Negative Control) in the presence of EC<sub>80</sub> agonist, prepare a solution containing 2% DMSO in Complete Buffer G. Add 10 µL of this solution to row C, columns 1–24 of a 384-well assay plate (see the plate layout in Section 7.3)

*For example:* Add 20 µL of 100% DMSO to 980 µL of Complete Buffer G.

3. Prepare a solution of control antagonist at 100X of the final desired maximum starting concentration using 100% DMSO.

*For example:* If the final desired maximum starting concentration of antagonist is 1 µM, prepare a solution of 100 µM antagonist in 100% DMSO.

4. For the “maximum antagonist” controls (Positive Control) dilute the 100X antagonist solution from step 3 to 2X using Complete Buffer G. Add 10 µL of this solution to row D, columns 1–24 in a 384-well assay plate (see the plate layout in Section 7.3).

*For example:* Add 10 µL of 100X antagonist solution to 490 µL of Complete Buffer G.

5. For the no agonist, no antagonist controls (Alternative Positive Control), add DMSO to Complete Buffer G for a final concentration of 2% DMSO. Add 10 µL of this solution to row E, columns 1–24 of a 384-well assay plate (see the plate layout in Section 7.3)

*For example:* Add 10 µL of 100% DMSO to 490 µL of Complete Buffer G.

### Prepare 2X Antagonist Titration

6. Prepare the serial dilution of antagonist as described for the agonist in Section 6.1, steps 5 through 7.

### Prepare 4X VDR-LBD

7. Prepare 4X VDR LBD as described in Section 6.1, step 8.
8. Add 5 µL of 4X VDR-LBD to rows A–E, columns 1–24 of the 384-well assay plate. We recommend adding from low to high concentration of ligand (right to left) to prevent ligand carry over.

### Prepare 4X Fluorescein-TRAP220/DRIP-2/4X Tb anti-GST Antibody

9. Prepare 4X Fluorescein-TRAP220/DRIP-2/4X Tb anti-GST Antibody as described in Section 6.1, step 10
10. Add 5 µL of 4X peptide/4X antibody solution to row E ONLY, columns 1–24 of the 384-well assay plate (see plate layout in Section 7.3).

### Prepare 4X Fluorescein-TRAP220/DRIP-2/4X Tb anti-GST Antibody/4X EC<sub>80</sub> Agonist

11. Prepare a 100X solution of the EC<sub>80</sub> of the agonist in Complete Buffer G.

*For example:* If the EC<sub>80</sub> of the agonist is 8 nM, prepare a 100X solution at 800 nM in Complete Buffer G by adding 4 µL of the 100X agonist solution (100 µM) from step 6.1.3 to 496 µL of Complete Buffer G.

12. Prepare a solution containing 0.4  $\mu\text{M}$  fluorescein-TRAP220/DRIP-2 (4X), 8 nM Tb anti-GST antibody (4X), and 4X of the agonist  $\text{EC}_{80}$  using Complete Buffer G. The concentration of fluorescein-TRAP220/DRIP-2 as supplied is 100  $\mu\text{M}$  and the concentration of Tb anti-GST antibody is indicated on both the vial label and the Certificate of Analysis (0.5 mg/mL =  $\sim 3.4 \mu\text{M}$  antibody using a Molecular Weight of 150kDa).


*For example:* Add 40  $\mu\text{L}$  of the 100X solution of the  $\text{EC}_{80}$  agonist, 4  $\mu\text{L}$  of 100  $\mu\text{M}$  fluorescein-TRAP220/DRIP-2, and 2.4  $\mu\text{L}$  of 3.4  $\mu\text{M}$  Tb anti-GST antibody to 954  $\mu\text{L}$  of Complete Buffer G.

13. Add 5  $\mu\text{L}$  of 4X peptide/4X antibody/4X  $\text{EC}_{80}$  agonist solution to rows A–D, columns 1–24 of the 384-well assay plate. (See the plate layout in Section 7.3).

### Plate Incubation and Reads

14. For plate incubations, follow steps 12 and 13 in Section 6.1.

## 7.3 Plate Layout



## 7.4 Antagonist Assay—Data Analysis

Calculate the TR-FRET ratio by dividing the emission at 520 nm by the emission at 495 nm. Generate a binding curve by plotting the emission ratio vs. the log [antagonist]. To determine the  $\text{IC}_{50}$  value, fit the data using an equation for a sigmoidal dose response (varying slope), as provided by GraphPad™ Prism 4.0 or other comparable graphing program.

The “no antagonist” and “maximum antagonist” control data (rows C and D) can be used to calculate  $Z'$ -factor based on the equation of Zhang *et al* (Zhang *et al.*, 1999).

## 7.5 Antagonist Assay—Reagent Volumes and Controls

The following table summarizes the reagent volumes and order of addition, along with potential controls for developing an antagonist mode assay. The protocol in Section 7.2 may be adapted, using the summary table below as a guide, to screen test compounds as needed by the user.


Assay	Reagent Additions	Purpose
Test Compound	<ol style="list-style-type: none"> <li>1. 10 <math>\mu</math>L 2X Test Compound (or dilution series)</li> <li>2. 5 <math>\mu</math>L 4X VDR-LBD</li> <li>3. 5 <math>\mu</math>L 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab/ EC<sub>80</sub> agonist</li> </ol>	Assess disruption of coactivator recruitment by competition of test compound and a known VDR agonist at the EC <sub>80</sub> for binding to VDR.
No antagonist (Negative control)	<ol style="list-style-type: none"> <li>1. 10 <math>\mu</math>L 2X Compound Solvent</li> <li>2. 5 <math>\mu</math>L 4X VDR-LBD</li> <li>3. 5 <math>\mu</math>L 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab/ EC<sub>80</sub> agonist</li> </ol>	Provides maximum FRET ratio for the antagonist assay.
Max Antagonist (Positive Control)	<ol style="list-style-type: none"> <li>1. 10 <math>\mu</math>L 2X known antagonist (or dilution series)</li> <li>2. 5 <math>\mu</math>L 4X VDR-LBD</li> <li>3. 5 <math>\mu</math>L 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab/EC<sub>80</sub> agonist</li> </ol>	Assess disruption of coactivator recruitment by competition of a known VDR antagonist at the EC <sub>80</sub> of a known agonist for binding to VDR.
No Agonist or Antagonist (Alternate Positive Control)	<ol style="list-style-type: none"> <li>1. 10 <math>\mu</math>L Assay Buffer with 2X Compound Solvent</li> <li>2. 5 <math>\mu</math>L Complete Buffer G</li> <li>3. 5 <math>\mu</math>L 4X FI-TRAP220/DRIP-2/Tb anti-GST Ab</li> </ol>	Recommended since antagonists are not established for VDR at this time and may stand in for the positive control. Provides bottom baseline for assay and can be used to assess diffusion enhanced TR-FRET.*

**Note:** All controls should contain the same percentage of solvent as the wells containing test compound.


\* Diffusion-enhanced TR-FRET occurs when the donor (Tb-anti-GST Antibody) passes by the acceptor (FI-TRAP220) in solution during the excited state lifetime of the donor and is not related to a binding event. At higher concentrations of donor or acceptor, the probability of diffusion-enhanced TR-FRET increases and results in a larger background signal.

## 8. Assay Pharmacology

4A.



4B.



Ligand	EC <sub>50</sub> (nM)
Calcitriol	0.84
25-hydroxyvitamin D3	160
1a-hydroxyvitamin D3	180
Dihydrotachysterol	—
Lithocholic Acid	—
Cholecalciferol	—

**Figure 4: Relative EC<sub>50</sub> Values of Selected Ligands for VDR-LBD in the LanthaScreen® TR-FRET VDR Coactivator Assay, Agonist Mode.** Serial dilutions of various test compounds (1% final DMSO concentration) were assayed in agonist mode (n = 4). Curves were fit using a sigmoidal dose-response equation (variable slope) in GraphPad™ Prism® 4.0. Figures 4a and 4b are data plotted differently. The values plotted in 4b have been normalized by the minimum TR-FRET ratio obtained for calcitriol so that the emission ratio for calcitriol starts at 1.0. There is no effect on the Z' or calculated EC<sub>50</sub>'s.



- Note:* Binding of different ligands may result in different conformations in the nuclear receptor and thus different affinities for the coregulator peptide. A lower peptide affinity will result in a decreased TR-FRET signal and a lower plateau in the dose response curve.
- Note:* The ligand  $EC_{50}$  determined in the assay is a composite of multiple equilibria, including ligand binding to receptor and peptide binding to ligand/receptor complex.

## 9. References

---

- Rachez, C., Gamble, M., Chang, C-PB., Atkins, G.B., Lazar, M.A., and Freedman, F.P. (2000) The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. *Mol. Cell. Biol.*, 20, 2718-2726
- Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. *J. Biomol. Screen.*, 4, 67-73

## 10. Notice to Purchaser

---

### Limited Use Label License No. 176: Lanthanide Chelates

This product is the subject of U.S. Patent No. 5,622,821, 5,639,615 and 5,656,433 and foreign equivalents licensed exclusively to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

The performance of this product is guaranteed for six months from the date of purchase if stored and handled properly.

This product and/or the use of this product is covered under one or more of the following US patents:

5,622,821, 5,639,615, 5,656,433, and 4,822,733, as well as pending patent applications owned by or licensed by Invitrogen Corporation.

Prism® is a registered trademark of GraphPad™ Software, Inc., San Diego, CA.

©2009 Life Technologies Corporation. All rights reserved. Reproduction without permission forbidden.